131 related articles for article (PubMed ID: 37909960)
1. Exploring
Mansoor A; Akhter A; Hamidi M; Roshan TM; Shabani-Rad MT; Stewart D
Anticancer Res; 2023 Nov; 43(11):4801-4807. PubMed ID: 37909960
[TBL] [Abstract][Full Text] [Related]
2. Expression of "DNA damage response" pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality.
Mansoor A; Kamran H; Rizwan H; Akhter A; Roshan TM; Shabani-Rad MT; Bavi P; Stewart D
Hematol Oncol; 2024 Jan; 42(1):e3225. PubMed ID: 37795760
[TBL] [Abstract][Full Text] [Related]
3. Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.
Mansoor A; Kamran H; Akhter A; Seno R; Torlakovic EE; Roshan TM; Shabani-Rad MT; Elyamany G; Minoo P; Stewart D
Mod Pathol; 2023 Aug; 36(8):100198. PubMed ID: 37105495
[TBL] [Abstract][Full Text] [Related]
4. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.
Venturutti L; Teater M; Zhai A; Chadburn A; Babiker L; Kim D; Béguelin W; Lee TC; Kim Y; Chin CR; Yewdell WT; Raught B; Phillip JM; Jiang Y; Staudt LM; Green MR; Chaudhuri J; Elemento O; Farinha P; Weng AP; Nissen MD; Steidl C; Morin RD; Scott DW; Privé GG; Melnick AM
Cell; 2020 Jul; 182(2):297-316.e27. PubMed ID: 32619424
[TBL] [Abstract][Full Text] [Related]
5. The Genetic Profile of Large B-Cell Lymphomas Presenting in the Ocular Adnexa.
Vest SD; Eriksen PRG; de Groot FA; de Groen RAL; Kleij AHR; Kirkegaard MK; Kamper P; Rasmussen PK; von Buchwald C; de Nully Brown P; Kiilgaard JF; Vermaat JSP; Heegaard S
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542066
[TBL] [Abstract][Full Text] [Related]
6. Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.
Berker N; Yeğen G; Özlük Y; Doğan Ö
Turk J Haematol; 2023 Aug; 40(3):162-173. PubMed ID: 37519110
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
Tagawa H
Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
[TBL] [Abstract][Full Text] [Related]
8. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.
Scott DW; Mungall KL; Ben-Neriah S; Rogic S; Morin RD; Slack GW; Tan KL; Chan FC; Lim RS; Connors JM; Marra MA; Mungall AJ; Steidl C; Gascoyne RD
Blood; 2012 May; 119(21):4949-52. PubMed ID: 22496164
[TBL] [Abstract][Full Text] [Related]
9. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the molecular landscape: a comparative analysis of PI3K and MAPK signaling pathways in plasmablastic lymphoma and diffuse large B-cell lymphoma with therapeutic implications.
Mansoor A; Akhter A; Kamran H; Minoo P; Stewart D
Hum Pathol; 2023 Nov; 141():102-109. PubMed ID: 37524252
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
12. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
[TBL] [Abstract][Full Text] [Related]
13. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
14. The feasibility of gene expression profiling generated in fine-needle aspiration specimens from patients with follicular lymphoma and diffuse large B-cell lymphoma.
Goy A; Stewart J; Barkoh BA; Remache YK; Katz R; Sneige N; Gilles F
Cancer; 2006 Feb; 108(1):10-20. PubMed ID: 16329118
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
16. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
17. The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM; Banham AH
Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3.
Borovecki A; Korać P; Nola M; Ivanković D; Jaksić B; Dominis M
Croat Med J; 2008 Oct; 49(5):625-35. PubMed ID: 18925696
[TBL] [Abstract][Full Text] [Related]
19. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
[TBL] [Abstract][Full Text] [Related]
20. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.
Schrader AMR; de Groen RAL; Willemze R; Jansen PM; Quint KD; van Wezel T; van Eijk R; Ruano D; Tensen CP; Hauben E; Woei-A-Jin FJSH; Busschots AM; van den Berg A; Diepstra A; Vermeer MH; Vermaat JSP
Virchows Arch; 2022 Mar; 480(3):667-675. PubMed ID: 35028710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]